new warnings about using rosiglitazone (Avandia) in patients with ANY degree of heart failure

You'll see new warnings about using rosiglitazone (Avandia) in patients with ANY degree of heart failure.

We already know to avoid giving rosiglitazone or pioglitazone (Actos) to patients with severe heart failure.

Now there's evidence that rosiglitazone increases cardiac risk in patients with LESS severe heart failure.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote